Related Experiment Videos
Hepatitis C infection: Updates on treatment guidelines
Renee Pozza1, Catherine Hill, Anna Marie Hefner
1Renee Pozza is an associate dean, professor, and NP at Azusa Pacific University and Southern California GI and Liver Centers, Azusa, Calif. Catherine Hill is an assistant professor at Azusa Pacific University, Azusa, Calif., and a hepatology NP at Southern California GI and Liver Centers, San Clemente, Calif. Anna Marie Hefner is an associate professor at Azusa Pacific University, Azusa, Calif., and an NP at Southern California GI and Liver Centers, Coronado, Calif. Beth Vawter is a family NP at Southern California Liver Centers, Riverside, Calif., and an educator at Azusa Pacific University, Azusa, Calif. Tarek Hassanein is a transplant hepatology outreach director at the University of Southern California, San Diego, and Medical Director of Southern California GI and Liver Centers, Coronado, Calif.
Abstract:
Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide. Due to the asymptomatic nature of the infection, many acute cases of HCV infection are left undiagnosed, so screening individuals at risk is an important public health priority. New medications offer sustained virologic response rates of over 95%, fewer adverse reactions, and shorter durations of therapy. This article reviews the new treatment guidelines for the evaluation and management of patients with HCV infection.